Excelsior Biopharma Total Current Liabilities

Excelsior Biopharma (6496.TWO) currently reports a total current liabilities of $450M as of June 2026. That compares with $190M in the prior-year period — up 138.1% year over year. Use the charts on this page to explore Excelsior Biopharma's total current liabilities history and peer comparisons.

Excelsior Biopharma's total current liabilities increased from $190M to $450M — a 138.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Excelsior Biopharma reported $450M in total current liabilities as of June 2026. That compares with $190M in the prior-year period — up 138.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $450M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Excelsior Biopharma, and consider following 6496.TWO for alerts when major investors trade the stock.